Fig. 2.
Effect of omalizumab on eosinophilia and indices of asthma severity: no significant reduction in eosinophils in the a sputum or b circulation, nor in the measurements of c fractional exhaled nitric oxide (FeNO), d asthma control (ACQ-5), or e FEV1 %predicted, could be documented for patients in the drug arm compared to placebo. Bars within the plots indicate the mean value for each group, and the delta (∆) values reflecting the mean absolute change within the group is give. Changes from baseline were compared for each arm using Wilcoxon paired analysis. P values were > 0.05, and were deemed non-significant